32498754 33217961 34319562 33540543 30704314 34025650 35585977 32984073 34240823 34225667 31627347 32823518 31817071 33004779 30815272 33212859 33976272 - Search Results

Year	Number of Results
2019	4
2020	6
2021	6
2022	2
2023	0

1

Inflammation as a treatment target in mood disorders: review.

Jones BDM, Daskalakis ZJ, Carvalho AF, Strawbridge R, Young AH, Mulsant BH, Husain MI. Jones BDM, et al. BJPsych Open. 2020 Jun 5;6(4):e60. doi: 10.1192/bjo.2020.43. BJPsych Open. 2020. PMID: 32498754 Free PMC article.

2

Anti-MAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn's Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection.

Qasem A, Elkamel E, Naser SA. Qasem A, et al. Biomedicines. 2020 Nov 18;8(11):513. doi: 10.3390/biomedicines8110513. Biomedicines. 2020. PMID: 33217961 Free PMC article.

3

Hypersensitivity and Immune-related Adverse Events in Biologic Therapy.

Waldron JL, Schworer SA, Kwan M. Waldron JL, et al. Clin Rev Allergy Immunol. 2022 Jun;62(3):413-431. doi: 10.1007/s12016-021-08879-w. Epub 2021 Jul 28. Clin Rev Allergy Immunol. 2022. PMID: 34319562 Review.

4

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.

Mercogliano MF, Bruni S, Mauro F, Elizalde PV, Schillaci R. Mercogliano MF, et al. Cancers (Basel). 2021 Feb 2;13(3):564. doi: 10.3390/cancers13030564. Cancers (Basel). 2021. PMID: 33540543 Free PMC article. Review.

5

Update upon the infection risk in patients receiving TNF alpha inhibitors.

Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Murdaca G, et al. Expert Opin Drug Saf. 2019 Mar;18(3):219-229. doi: 10.1080/14740338.2019.1577817. Epub 2019 Feb 27. Expert Opin Drug Saf. 2019. PMID: 30704314 Review.

6

Anti-TNF-α agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling.

Keewan E, Beg S, Naser SA. Keewan E, et al. Front Immunol. 2021 May 6;12:641295. doi: 10.3389/fimmu.2021.641295. eCollection 2021. Front Immunol. 2021. PMID: 34025650 Free PMC article.

7

Attenuation of Excess TNF-α Release in Crohn's Disease by Silencing of iRHOMs 1/2 and the Restoration of TGF-β Mediated Immunosuppression Through Modulation of TACE Trafficking.

Louis TJ, Qasem A, Naser SA. Louis TJ, et al. Front Immunol. 2022 May 2;13:887830. doi: 10.3389/fimmu.2022.887830. eCollection 2022. Front Immunol. 2022. PMID: 35585977 Free PMC article.

8

Comprehensive Determination of Mycobacterium tuberculosis and Nontuberculous Mycobacteria From Targeted Capture Sequencing.

He Y, Gong Z, Zhao X, Zhang D, Zhang Z. He Y, et al. Front Cell Infect Microbiol. 2020 Sep 1;10:449. doi: 10.3389/fcimb.2020.00449. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32984073 Free PMC article.

9

Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease.

Yang QY, Liu YJ, Xu Y, Zhang L, Wang CD. Yang QY, et al. J Dig Dis. 2021 Aug;22(8):473-480. doi: 10.1111/1751-2980.13032. Epub 2021 Aug 3. J Dig Dis. 2021. PMID: 34240823

10

Utility of interferon gamma/tumor necrosis factor alpha FluoroSpot assay in differentiation between active tuberculosis and latent tuberculosis infection: a pilot study.

Zhang L, Wan S, Zhou Z, Zhang Y, Liu X. Zhang L, et al. BMC Infect Dis. 2021 Jul 6;21(1):651. doi: 10.1186/s12879-021-06351-w. BMC Infect Dis. 2021. PMID: 34225667 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results